TITLE

Quad Doesn't Disappoint: 4Q NDA Filing on Tap for Gilead

AUTHOR(S)
Powers, Marie
PUB. DATE
September 2011
SOURCE
BioWorld Today;9/21/2011, Vol. 22 Issue 183, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the second pivotal Phase III trial of the HIV Quad regimen, which includes elvitegravir, cobicistat, emtricitabin and tenofovir disoproxil fumarate, from Gilead Sciences Inc. The trial reportedly meet the expectation of Gilead Sciences and analysts by showing noninferiority at week 48 of the trial compared to ritonavir-boosted atazanavir plus Truvada. Gilead Sciences is planning to request a review for the approval of Quad by the U.S. Food and Drug Administration (FDA).
ACCESSION #
65645239

 

Related Articles

  • Emtriva Receives FDA Nod.  // Guide;Nov2003, Vol. 23 Issue 11, p46 

    Reports on the U.S. Food and Drug Administration's approval of Emtriva for use in combination with other antiretroviral agents in the treatment of HIV infection. Assessment of nucleoside reverse transcriptase inhibitor Emtriva by genotypic or phenotypic testing; Increase in mean baseline CD4...

  • FDA Approves Viread for HIV-1 Infection.  // FDA Consumer;Jan/Feb2002, Vol. 36 Issue 1, p5 

    Reports that the United States Food and Drug Administration has approved Viread, an antiviral drug for the treatment of HIV-1 infection in combination with other antiretroviral medicines. Most frequently reported adverse events among patients in the clinical trials; Marketer of Viread.

  • Prodrug of tenofovir diphosphate approved for combination HIV therapy.  // American Journal of Health-System Pharmacy;1/1/2002, Vol. 59 Issue 1, p18 

    Reports on United States Food and Drug Administration's market approval of tenofovir disopropxil fumarate for the treatment of HIV. Drug effectiveness; Findings of clinical trials; Drug bioavailability; Dosage recommendation; Adverse effects of the drug.

  • Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. Theys, K.; Snoeck, J.; Vercauteren, J.; Abecasis, A. B.; Vandamme, A.-M.; Camacho, R. J. // Journal of Antimicrobial Chemotherapy (JAC);Feb2013, Vol. 68 Issue 2, p419 

    Objectives The use of tenofovir is highly associated with the emergence of mutation K65R, which confers broad resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs), especially when tenofovir is combined with other NRTIs also selecting for K65R. Although recent...

  • Enfuvirtide. Coleman, Craig I.; Musial, Bogdan L.; Ross, Jack // Formulary;Apr2003, Vol. 38 Issue 4, p204 

    Focuses on enfuvirtide, the first member of antiretrovirals to gain U.S. Food and Drug approval for the treatment of HIV-1 infection. Pharmacology; Pharmacokinetics; Clinical trials of enfuvirtide; Safety and tolerability; Drug interactions; Dosage and administration; Cost. INSET: Formulary...

  • FDA Panel Recommends Approval of Quad Regimen. Shaffer, Catherine // BioWorld Today;5/14/2012, Vol. 23 Issue 93, p1 

    The article reports on the vote by the U.S. Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee (AVAC) in favor of approval for Gilead Inc.'s single-tablet Quad regimen for treatment-naive adult patients with HIV-1. The safety data of the Quad regimen was closely examined by...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Sep2007, Vol. 21 Issue 9, p702 

    The article offers news briefs related to antiviral agents in the U.S. The Selzentry tablet, a CCR5 antagonist from Pfizer Inc., was approved by the Food and Drug Administration (FDA). The Antiviral Drugs Advisory Committee of FDA voted to recommend the approval of Isentress, a raltegravir in...

  • FDA panel OKs new class of HIV drug. Roehr, Bob // Bay Area Reporter;4/26/2007, Vol. 37 Issue 17, p17 

    The article reports that a committee of the U.S. Food and Drug Administration has recommended approval of Pfizer Inc.'s CCR5 inhibitor maraviroc, trademarked Celsentri. Maraviroc belongs to a class of anti-HIV drugs developed for heavily treatment-experienced patients. It works against the R5...

  • Maraviroc for Treatment-Naive Patients with HIV-1 Infection: Is the Glass Half Empty or Half Full? Sax, Paul E. // Journal of Infectious Diseases;3/15/2010, Vol. 201 Issue 6, p797 

    In this article the author discusses the concerns related to maraviroc, a treatment for HIV-infected patients. It mentions that the approved maraviroc, by the U.S. Food and Drug Administration, is said to be used to treat patients using CCR5 receptor (R5 virus). It states that the downside of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics